Clinical Trials Current Clinical trials for CAPS disorders. Clinical Trials for patients with Cryopyrin-Associated Periodic Syndromes NIH NOMID Clinical Trial with Canakinumab Study for treating patients with Ilaris that are over the age of 2 years with NOMID. NIH NOMID Clinical Trial with Anakinra Patients over the age of 2 years with NOMID can enroll in this clinical trial using anakinra to treat their symptoms. Natural History of NOMID Clinical Trial Urticaria and Familial Cold Autoinflammatory Syndrome (FCAS) NIH study in bethesda, Maryland for patients with FCAS. CAPS Clinical Trial with Ilaris in Japan Japanese CAPS patients over the age of 2 years can enroll in this study with the new medication Ilaris. Clinical Trials for other Autoinflammatory Syndromes Natural History Study for patients with NOMID/CAPS, DIRA, CRMO, Still's Behcet's and unidentified Autoinflammatory Diseases Autoinflammatory multisystem diseases are a group of diseases that are characterized by recurrent episodes of systemic inflammation as well as organ specific inflammation that can involve the skin, eyes, joints, bones, serosal surfaces, inner ear, and brain. The prominent role of IL-1 in the pathogenesis of these disorders has first become evident through the discovery of mutations in CIAS1 causing the cryopyrin-associated periodic syndromes (CAPS) including the most severe presentation Neonatal Onset Multisystem Inflammatory Disease (NOMID). We recently identified a new autoinflammatory disease DIRA (Deficiency of IL-1 Receptor Antagonist), a disease that is caused by mutations in IL1RN. Therapy with anakinra, the IL-1 receptor antagonist, can be life-saving. We plan to extend this protocol to explore additional rare diseases including the spectrum CRMO (Chronic Recurrent Multifocal Osteomyelitis), Still's disease, and Behçet's disease (BD) all of which may involve dysregulation of IL-1. In this research protocol we seek to comprehensively evaluate affected patients clinically, genetically, immunologically, and endocrinologically. In addition we intend to evaluate long term outcome and biomarkers. Eligibility for ongoing and planned treatment protocols will be determined by screening patients in this protocol. We plan to evaluate patients on a consultative basis for other autoinflammatory diseases for possible enrollment into this study. IL-1 Trap for Autoinflammatory Diseases Rilonacept for FMF Phase II Rilonacept for FMF MRI study for FMF patients FMF genetics study MVK study (HIDS) and cholesterol synthesis defects Search for more Clinical Trials at clinicaltrials.gov There may be much more current studies available if you search the database by disease condition on this site. |Welcome!| |Purpose & Goals| |Syndrome Info.| |Clinical Trials| |CAPS Guidebook| |Research Findings| |Syndrome photos| |Internet Links| |Shop/Support| |CAPS Specialists| |News & Events| |Donate| |Annual Reports| |Thanks to Our Donors| |Feedback Survey| |Contact Us| |Survey| |Buy T shirts/totes|